Delivery Order HHSN261201600018I-HHSN26100001

<p>This is a $1,784.00 firm fixed price delivery order contract awarded by the National Cancer Institute, a civilian agency, to Battelle Memorial Institute for initial administrative charges related to a pre-clinical toxicology study of a drug being developed for cancer patients. The contract is an order placed under the Toxicology of Drugs Developed for Cancer Patients indefinite-delivery indefinite-quantity (IDIQ) contract vehicle. No set-aside was used for this award.</p>

This is a delivery order under the Toxicology of Drugs Developed for Cancer Patients contract vehicle, awarded by the National Cancer Institute (NCI) to Battelle Memorial Institute. The $248,269.21 cost-plus-fixed-fee contract is for a pre-clinical toxicity study to characterize the toxicity of potential anticancer compounds following multiple dose administration to rats. The contract runs from January 18, 2017 to June 30, 2018. No set-aside designation is mentioned. Battelle frequently serves...

This is a $1,010.00 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for a &quot;Kick Off Meeting, Preclinical Pharmacokinetic &amp; Pharmacology Evaluations of Agents Being Developed for Cancer Patients&quot; with a performance period from July 1, 2016 to September 30, 2016. This work is being performed under NCI's Pharmacokinetic and Pharmacology Evaluations for...

This is a $36,506,288.06 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to Theradex Systems, Inc. for clinical trials monitoring services. The contract has a performance period from May 1, 2017 to April 30, 2022. The contract supports NCI's Experimental Therapeutics Clinical Trials Network (ETCTN), National Clinical Trials Network (NCTN), and National Community Oncology Research Program (NCORP), as well as the NCI COVID-19 in Cancer Patients Study (NCCAPS) and the...

This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $159,319,089.46 contract, which does not have a set-aside designation, is for preclinical toxicology and pharmacology studies to support Investigational New Drug (IND) applications for small molecule, biologic, and RNA therapeutic candidates across various...

This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $1,259,678.78 contract is to provide support for the preclinical development of an endoxifen gel, including pharmacology, toxicology, and safety studies to support an Investigational New Drug (IND) application. This contract is part of the NCI's PREVENT...

This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Illinois. The contract is valued at $761,043.02 and is part of the larger &quot;Toxicology of Drugs Developed for Cancer Patients&quot; indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The purpose of this award is to conduct pre-clinical toxicology studies of a drug candidate, specifically DNA methyltransferase-TdCyd, for potential use in...

This is a Cost Plus Fixed Fee delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Battelle Memorial Institute, a non-profit organization and manufacturer of goods. The contract is for an exploratory toxicology study in dogs of an MCL-1 inhibitor drug being developed for cancer and other diseases. The contract has a potential value of $116,039 and a completion date of June 30, 2021. It is a task...

This firm fixed-price purchase order for $86,631 was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Labcorp Early Development Laboratories Inc. to perform 60-month stability testing of two lots of LMB-100 drug product. LMB-100 is an anti-mesothelin immunotoxin under clinical trials for certain cancers. The prime contractor Labcorp will conduct a battery of assays to ensure the identity, potency, and safety of the drug product...

This is a delivery order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to IIT Research Institute, a non-profit research organization, for a series of toxicology studies in rabbits for drugs developed for cancer patients. The $487,537.00 contract is part of the Toxicology of Drugs Developed for Cancer Patients indefinite delivery/indefinite quantity contract vehicle and includes dose range finding, preliminary embryo fetal...